|
186 Products |
| 186 Products |
|
1696 Diseases |  |
95004 News |  |
| «12...368369370371372373374375376377378...10671068» |
- || budesonide / Generic mfg.
There was never a clear set of options for the PCP’s to follow. This applies to monoclonal antibodies, the new antivirals, or other effective treatments such as fluoxamine, budesonide, methlyprednisolone, cyproheptadine, etc. Many opted for the easy way out. “ stay home “. (Twitter) - Feb 16, 2022
- | cyclosporine / Generic mfg.
Journal: A COVID-19 Risk Reduction Strategy for the Treatment of Acute Vogt-Koyanagi-Harada Disease Utilizing the Antiviral Potential of Cyclosporine. (Pubmed Central) - Feb 16, 2022
Oral cyclosporine as the initial systemic treatment of acute VKH disease, in combination with sub-Tenon injection of triamcinolone acetonid, lead to favorable clinical outcomes. Due to the known antiviral properties of cyclosporine, we suggest that this may represent a good treatment strategy for patients during the COVID-19 pandemic.
- | methylprednisolone oral / Generic mfg., trimethoprim/sulfamethoxazole / Generic mfg.
Trial completion date, Trial primary completion date: Short-term Steroid Therapy in Patients With P. Jirovecii Pneumonia Due to HIV / AIDS (clinicaltrials.gov) - Feb 16, 2022
P=N/A, N=196, Enrolling by invitation, Sponsor: Centro de Investigaci
Due to the known antiviral properties of cyclosporine, we suggest that this may represent a good treatment strategy for patients during the COVID-19 pandemic. Trial completion date: Feb 2023 --> Dec 2024 | Trial primary completion date: Dec 2022 --> Dec 2023
- |||| traneurocin oral (NA-831) / NeuroActiva
Trial completion date, Trial primary completion date, Combination therapy: NATADEX: NA-831, Atazanavir and Dexamethasone Combination Therapy for the Treatment of COVID-19 Infection (clinicaltrials.gov) - Feb 16, 2022
P2/3, N=525, Recruiting, Sponsor: NeuroActiva, Inc.
Trial completion date: Feb 2023 --> Dec 2024 | Trial primary completion date: Dec 2022 --> Dec 2023 Trial completion date: Feb 2021 --> Dec 2023 | Trial primary completion date: Dec 2020 --> Dec 2023
- Darzalex IV (daratumumab) / J&J
A case of Multiple Myeloma presenting with acquired von Willebrand Syndrome as initial symptom (hall 1; hall 2; hall 3; hall 4; hall 5) - Feb 16, 2022 - Abstract #GTH2022GTH_230;
By controlling paraproteinemia, myeloma specific therapy is able to ameliorate bleeding symptoms. However, this case illustrates that complete disappearance of the paraprotein is necessary to restore von Willebrand factor function.
- dexamethasone / Generic mfg.
A case of thrombotic thrombocytopenic purpura (iTTP) associated with angioimmunoblastic T-cell lymphoma (AITL) (hall 1; hall 2; hall 3; hall 4; hall 5) - Feb 16, 2022 - Abstract #GTH2022GTH_224;
To our knowledge this is the first reported case of an iTTP associated with angioimmunoblastic T-cell lymphoma. Due to the poor prognosis of the lymphoma, long term cure may be achieved using high dose chemotherapy and autologous peripheral stem cell transplantation (PBSCT).
- | New P3 trial: HELEN-009: Fosaprepitant , Tropisetron and Olanzapine for the Prevention of Nausea and Vomiting in Patients With Breast Cancer (clinicaltrials.gov) - Feb 16, 2022
P3, N=403, Active, not recruiting, Sponsor: Henan Cancer Hospital
- ||| dexamethasone / Generic mfg.
Head-to-Head: Well this is interesting - Well done! Interscalene Brachial Plexus Block with Liposomal Bupivacaine versus Standard Bupivacaine with Perineural Dexamethasone: A Noninferiority Trial @sgmemtsoudis @shaskinsMD @ChrisWuMD @HSSAnesthesia @ASRA_Society https://t.co/LTLGHNykzc (Twitter) - Feb 15, 2022
- | dexamethasone / Generic mfg.
Journal: Mutant glucocorticoid receptor binding elements on the interleukin-6 promoter regulate dexamethasone effects. (Pubmed Central) - Feb 15, 2022
Due to the poor prognosis of the lymphoma, long term cure may be achieved using high dose chemotherapy and autologous peripheral stem cell transplantation (PBSCT). We concluded that selective GR2 modulator might exert agonistic and antagonistic effects and could activate crucial signaling pathways during the LPS-stimulated inflammatory process.
- | dexamethasone / Generic mfg.
Journal: Glucocorticoid-induced dose-related and site-specific bone remodeling, microstructure, and mechanical changes in cancellous and cortical bones. (Pubmed Central) - Feb 15, 2022
Thirty-one female Sprague-Dawley rats were randomly divided into three dexamethasone (Dex) dosage groups, 1.0, 2.5, and 5.0 mg/kg twice a week for 8 weeks, and one control group treated with saline...In summary, Bone remodeling was dose-dependently inhibited in cancellous bones but enhanced in intracortical bones. The non-uniform distribution of trabecular bone and increased porosity in the inner edge of cortical bone were both in parallel with GC dosage, and the porosity increase was more likely to occur, leading to reduced cortical mechanical strength.
- || deferiprone / Generic mfg., dexamethasone injection / Generic mfg.
Clinical, Journal, HEOR: Drug utilization study and cost analysis of adult β-thalassemia major patient therapy at Dr. Soetomo General Hospital Surabaya. (Pubmed Central) - Feb 15, 2022
However, deferasirox also yielded the highest cost. Yet, overall, the hospital gained profit from national health insurance claims.
- | dexamethasone / Generic mfg.
Preclinical, Journal, PD(L)-1 Biomarker, IO biomarker: Dexamethasone reduces autoantibody levels in MRL/lpr mice by inhibiting Tfh cell responses. (Pubmed Central) - Feb 15, 2022
In brief, Dex inhibited the Tfh development, which relies on many other transcription factors in addition to Bcl-6. Our data indicate that Dex can be used as a Tfh cell inhibitor in SLE.
- || Clinical, Journal: Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis. (Pubmed Central) - Feb 15, 2022
In this retrospective study of 305 NDMM patients, VTE rates in those treated with carfilzomib, lenalidomide, dexamethasone (KRD) + aspirin (ASA), bortezomib, lenalidomide, dexamethasone (RVD) + ASA, and KRD + rivaroxaban were statistically significant, 16·1%, 4·8%, and 4·8%, respectively. The findings confirm a higher incidence of VTE when using KRD induction compared to RVD induction and reveal that the use of low-dose rivaroxaban thromboprophylaxis can mitigate this risk without an observable increase in bleeding rates.
- || Oncocort (pegylated liposomal dexamethasone) / Enceladus
Clinical, PK/PD data, Journal: An exploratory first-in-man study to investigate the pharmacokinetics and safety of liposomal dexamethasone at a 2- and 1-week interval in patients with metastatic castration resistant prostate cancer. (Pubmed Central) - Feb 15, 2022
The data presented support further clinical investigation in well-powered studies. Clinical trial registration: ISRCTN 10011715.
- | dexamethasone / Generic mfg.
Journal: An Optimized Pathway for the Differential Diagnosis of ACTH-Dependent Cushing's Syndrome Based on Low-Dose Dexamethasone Suppression Test. (Pubmed Central) - Feb 15, 2022
LDDST had similar value to HDDST in differentiating CD and EAS using the specific cutoff point. The pathway that combined LDDST and BIPSS could differentiate CD and EAS accurately.
- || Breztri Aerosphere (budesonide/formoterol fumarate/glycopyrronium) / AstraZeneca
Clinical, Journal: A scintigraphy study of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler in patients with moderate-to-very severe chronic obstructive pulmonary disease. (Pubmed Central) - Feb 15, 2022
P1
The pathway that combined LDDST and BIPSS could differentiate CD and EAS accurately. Radiolabeled BGF 320/18/9.6 μg was efficiently delivered and deposited throughout the entire lung, including large and small airways, in patients with moderate-to-very severe COPD, with similar deposition in patients with moderate COPD and patients with severe/very severe COPD.
- || Melflufen (melphalan flufenamide) / Oncopeptides
Clinical, P2 data, Journal, Patient reported outcomes: Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study. (Pubmed Central) - Feb 15, 2022
P2
These findings support the notion that treatment with melflufen plus dexamethasone may sustain or improve HRQoL over time in patients with RRMM, including in patients with triple-class-refractory disease for whom outcomes are generally worse. The clinical benefits observed in patients from the HORIZON trial are encouraging and supportive of translation into real-world practice.
- || dexamethasone / Generic mfg., cisplatin / Generic mfg., everolimus / Generic mfg.
Clinical, P1/2 data, Journal, Combination therapy: Reinduction therapy with everolimus in combination with dexamethasone, high-dose cytarabin and cisplatinum in patients with relapsed or refractory classical Hodgkin lymphoma: an experimental phase I/II multicentre trial of the German Hodgkin Study Group (GHSG HD-R3i). (Pubmed Central) - Feb 15, 2022
With a CT-based CR rate of 27% (n = 12/45) after two cycles of everDHAP the trial did not meet the primary end-point. Adding everolimus to DHAP is thus feasible; however, the everDHAP regimen failed to show an improved efficacy.
- | dexamethasone / Generic mfg.
Journal: The Progestin Medroxyprogesterone Acetate Affects HIV-1 Production in Human Lymphoid Tissue Explants in a Dose-Dependent and Glucocorticoid-like Fashion. (Pubmed Central) - Feb 15, 2022
Blockage of the progesterone and glucocorticoid receptors with mifepristone abolished all observed changes in HIV-1 and cytokine production, and was associated with increased IL-22 levels in HIV-infected explants. Our data indicate that elevated doses of MPA may affect the immune responses in lymphoid tissue in a glucocorticoid-like fashion with an immediate impact on local HIV-1 replication.
- | dexamethasone / Generic mfg.
Journal: Applications of the SR4G Transgenic Zebrafish Line for Biomonitoring of Stress-Disrupting Compounds: A Proof-of-Concept Study. (Pubmed Central) - Feb 15, 2022
We employed zebrafish larva (transgenic SR4G line) with a cortisol-inducible green fluorescence protein reporter (eGFP) as a model to detect stress responses upon exposure to compounds with environmental impact, including bisphenol A (BPA), vinclozolin (VIN), and fluoxetine (FLX)...Hydrocortisone (CORT)and dexamethasone (DEX) were used as positive and negative controls, respectively...Our findings support the use of SR4G transgenic larvae as an in vivo biomonitoring model to screen chemicals for their stress-disrupting potentials. This is important because there is increasing evidence that brief exposures to environmental pollutants modify the stress response and critical coping behaviors for several generations.
- | dexamethasone / Generic mfg.
Biomarker, Observational data, Retrospective data, Journal: Coronavirus Disease 2019 Temperature Trajectories Correlate With Hyperinflammatory and Hypercoagulable Subphenotypes. (Pubmed Central) - Feb 15, 2022
Hyperthermic slow resolvers had elevated inflammatory markers and the highest odds of mortality, suggesting a hyperinflammatory subphenotype. Future work should investigate whether temperature subphenotypes benefit from targeted antithrombotic and anti-inflammatory strategies.
- | budesonide/salbutamol (PT027) / AstraZeneca, Avillion
Journal, Monotherapy: Effects of nebulized budesonide plus salbutamol and nebulized salbutamol monotherapy on mild to moderate acute exacerbation of asthma in children: A comparative study. (Pubmed Central) - Feb 15, 2022
Future work should investigate whether temperature subphenotypes benefit from targeted antithrombotic and anti-inflammatory strategies. Treatment of asthmatic children having mild to moderate acute exacerbation with a combination of nebulized budesonide plus salbutamol resulted in significant clinical improvement and reduction in the duration of emergency department stay compared to children on nebulized salbutamol monotherapy.
- | dexamethasone / Generic mfg.
Journal: Rare case of renal Ewing sarcoma presenting as ectopic Cushing syndrome in a 12-year-old girl. (Pubmed Central) - Feb 15, 2022
High dose dexamethasone suppression test confirmed an ectopic source of ACTH secretion and CT scan revealed a mass in the right kidney which was laparoscopically excised...Our case highlights the rare presentation of renal Ewing sarcoma (RES) as CS. To the best of our knowledge, this is only the second case report of RES/primitive neuroectodermal tumour of the kidney presenting as CS in paediatric age group and first with a concomitant pituitary incidentaloma.
- || dexamethasone / Generic mfg.
Dexamethasone definitely increases duration of block but not convinced it does so through a perineural mechanism. I believe you can also get effect through IV administration, but regardless, this combination was non-inferior to liposomal bupivacaine (Twitter) - Feb 15, 2022
- ||| dexamethasone / Generic mfg.
Bupivacaine + dexamethasone was non-inferior to liposomal bupivacaine for interscalene brachial plexus blocks. Another peer-reviewed, scientific study showing no benefit to liposomal bupivacaine when compared to less expensive options. @_Anesthesiology https://t.co/YDDkYA8QOy (Twitter) - Feb 15, 2022
- | budesonide inhalation solution (AQ001S) / Aquilon
Trial completion date, Trial primary completion date: BOREAS: Crossover Trial to Assess Efficacy and Safety of Inhaled AQ001S Compared to a Budesonide Suspension in Mild Asthmatics (clinicaltrials.gov) - Feb 15, 2022
P1/2, N=24, Recruiting, Sponsor: Aquilon Pharmaceuticals S.A.
To the best of our knowledge, this is only the second case report of RES/primitive neuroectodermal tumour of the kidney presenting as CS in paediatric age group and first with a concomitant pituitary incidentaloma. Trial completion date: Nov 2021 --> May 2022 | Trial primary completion date: Nov 2021 --> May 2022
- | Actemra IV (tocilizumab) / Roche, JW Pharma
Journal: Pulmonary Function and Chest Computed Tomography (CT) Scan Findings After Antifibrotic Treatment for COVID-19-Related Pulmonary Fibrosis. (Pubmed Central) - Feb 15, 2022
An additional course of hydrocortisone was given due to asthma exacerbation, gradually liberating her from the HFNC...DLCO remained moderately reduced (59% predicted) but her 6MWD (457 meters) and CT scan results continued to improve. CONCLUSIONS Nintedanib, along with other interventions, may have potentially improved pulmonary function and CT scan findings in a COVID-19 survivor with pulmonary fibrosis 6 months after treatment.
- | dexamethasone / Generic mfg., midazolam hydrochloride / Generic mfg.
Journal: PBPK Modelling of Dexamethasone in Patients With COVID-19 and Liver Disease. (Pubmed Central) - Feb 15, 2022
The exposure of DEX in different stages of LD was predicted through PBPK modelling, providing a rational framework to predict PK in complex clinical scenarios related to COVID-19. Model simulations suggest dose adjustments of DEX in LD patients are not necessary considering the low dose administered in the COVID-19 protocol.
- | dexamethasone / Generic mfg.
Journal: Histone Deacetylation Controls Xylem Vessel Cell Differentiation via Transcriptional Regulation of a Transcription Repressor Complex OFP1/4-MYB75-KNAT7-BLH6. (Pubmed Central) - Feb 15, 2022
We tested the effects of cellular stress inducers on VND7-induced differentiation of xylem vessel cells with the VND7-VP16-GR system, in which VND7 activity is post-translationally induced by dexamethasone application...Thus, the negative effects of HDAC inhibitors on xylem vessel cell differentiation are mediated, at least partly, by the abnormal upregulation of the transcriptional repressor complex OFP1/4-MYB75-KNAT7-BLH6. Collectively, our findings suggest that active regulation of histone deacetylation by HDACs is involved in xylem vessel cell differentiation via the OFP1/4-MYB75-KNAT7-BLH6 complex.
- | dexamethasone / Generic mfg.
Journal: Identification of circRNA Expression Profiles in BMSCs from Glucocorticoid-Induced Osteoporosis Model. (Pubmed Central) - Feb 15, 2022
A small animal GIOP model was developed in Sprague-Dawley rats given daily intraperitoneal doses of the synthetic glucocorticoid dexamethasone...Furthermore, the signalling pathways associated with these differentially expressed circRNAs were predicted. The present study identified circARSB, circAKT3, circPTEN, and circTRPM7 as being associated with osteogenic differentiation during GIOP through a circRNA-targeted miRNA-mRNA axis, which might provide insight into the pathophysiological mechanism of GIOP.
- | dexamethasone / Generic mfg.
Journal: Comparison between botulinum toxin and steroid septal injection in the treatment of allergic rhinitis. (Pubmed Central) - Feb 15, 2022
Ninety-five patients were randomized to receive botulinum toxin, dexamethasone, or normal saline (group A, group B, and placebo, respectively)...Botulinum toxin septal injection is a safe treatment option for AR and improves subjective nasal symptoms for 3 months. Botulinum toxin A injection tended to be more effective than steroid septal injection in terms of duration and degree.Level of Evidence: 2b, individual cohort study.
- | hydrocortisone / Generic mfg.
Observational data, Retrospective data, Journal: Clinical Utilization of Stress Dose Hydrocortisone in Adult Patients With Septic Shock: A Retrospective Observational Study at a Large Academic Medical Center. (Pubmed Central) - Feb 15, 2022
Patients who received hydrocortisone were more severely ill than those that did not, making retrospective evaluation of this question challenging. These results highlight the wide variability and heterogeneity in hydrocortisone use in clinical practice.
- || Trelegy Ellipta (fluticasone furoate/umeclidinium bromide/vilanterol) / GSK, Innoviva, Theravance Biopharma
Review, Journal: Trends and Characteristics of Global Initiative for Chronic Obstructive Lung Disease Guidelines-Discordant Prescribing of Triple Therapy Among Patients with COPD. (Pubmed Central) - Feb 15, 2022
TT comprised ≥30 days of overlapping LAMA, LABA, and ICS treatments (open TT), or single-inhaler fluticasone furoate/umeclidinium/vilanterol (closed TT)...A substantial proportion of COPD patients initiating TT do not meet GOLD recommendations regarding exacerbation history and/or prior maintenance therapy. Compared with open TT, closed TT initiators were more likely to be dual-discordant.
- | Rituxan (rituximab) / Roche
Trial completion date: Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - Feb 15, 2022
P2, N=349, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Compared with open TT, closed TT initiators were more likely to be dual-discordant. Trial completion date: Dec 2021 --> Dec 2022
- | Iclusig (ponatinib) / Takeda, Otsuka
Trial completion date, Trial primary completion date: Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Feb 15, 2022
P2, N=100, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Dec 2021 --> Dec 2022 Trial completion date: Oct 2021 --> Oct 2022 | Trial primary completion date: Oct 2021 --> Oct 2022
- | bortezomib / Generic mfg.
Trial completion date, Combination therapy: Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) - Feb 15, 2022
P2, N=45, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Trial completion date: Oct 2021 --> Oct 2022 | Trial primary completion date: Oct 2021 --> Oct 2022 Trial completion date: Aug 2022 --> Aug 2023
- ||| miricorilant (CORT118335) / Corcept Therap
Enrollment change: GRATITUDE: A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications (clinicaltrials.gov) - Feb 15, 2022
P2, N=70, Recruiting, Sponsor: Corcept Therapeutics
Trial completion date: Aug 2022 --> Aug 2023 N=100 --> 70
- ||| Blenrep (belantamab mafodotin-blmf) / GSK
Enrollment change, Combination therapy: Multi-Center Study of GSK2857916 in Combination With Pomalidomide and Dex (clinicaltrials.gov) - Feb 15, 2022
P1/2, N=96, Recruiting, Sponsor: Canadian Myeloma Research Group
N=100 --> 70 N=62 --> 96
- |||| Clinical, Combination therapy: Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients https://t.co/6uprUuXkcV (Twitter) - Feb 15, 2022
- | Melflufen (melphalan flufenamide) / Oncopeptides
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: A Clinical Study of Melphalan Flufenamide (Melflufen) and Dexamethasone for Patients With Immunoglobulin Light Chain (AL) Amyloidosis (clinicaltrials.gov) - Feb 15, 2022
P1/2, N=6, Terminated, Sponsor: Oncopeptides AB
N=62 --> 96 N=46 --> 6 | Trial completion date: Apr 2024 --> Jan 2022 | Active, not recruiting --> Terminated | Trial primary completion date: Feb 2023 --> Jan 2022; The sponsor decided to terminate the study following an FDA request of a partial clinical hold.
- || miricorilant (CORT118335) / Corcept Therap
Enrollment closed, Trial completion date, Trial primary completion date: Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia While Taking Antipsychotic Medications (GRATITUDE II) (clinicaltrials.gov) - Feb 15, 2022
P2, N=150, Active, not recruiting, Sponsor: Corcept Therapeutics
N=46 --> 6 | Trial completion date: Apr 2024 --> Jan 2022 | Active, not recruiting --> Terminated | Trial primary completion date: Feb 2023 --> Jan 2022; The sponsor decided to terminate the study following an FDA request of a partial clinical hold. Recruiting --> Active, not recruiting | Trial completion date: Jun 2022 --> Oct 2022 | Trial primary completion date: May 2022 --> Oct 2022
- |||| dexamethasone / Generic mfg., lenalidomide / Generic mfg., Ninlaro (ixazomib) / Takeda
Clinical, Real-world evidence: Suzanne Fanning, DO, and Joshua Richter, MD, discuss clinical implications of a real-world study of ixazomib, lenalidomide, and dexamethasone compared with lenalidomide and dexamethasone in patients with relapsed/refractory #mmsm. @JoshuaRichterMD https://t.co/FL8qpV1Ewj (Twitter) - Feb 15, 2022
- | dexamethasone / Generic mfg.
Trial completion date, Trial primary completion date: Dexamethasone and COVID-19 Inpatient Mortality (clinicaltrials.gov) - Feb 15, 2022
P=N/A, N=20000, Active, not recruiting, Sponsor: Aetion, Inc.
Recruiting --> Active, not recruiting | Trial completion date: Jun 2022 --> Oct 2022 | Trial primary completion date: May 2022 --> Oct 2022 Trial completion date: Aug 2021 --> Jun 2022 | Trial primary completion date: Aug 2021 --> Dec 2021
- || dexamethasone / Generic mfg., fluvoxamine / Generic mfg., nitazoxanide / Generic mfg.
Budesonside Sotrivimab Fluvoxamine Dexamethasone Nitazoxanide HCQ Ivermectin (Twitter) - Feb 14, 2022
- | Spiriva Respimat (tiotropium bromide) / Boehringer Ingelheim, Ultibro (glycopyrronium/indacaterol) / Novartis
Trial completion: INTUITIVE: Description of the Ability to Learn How to Handle Inhaler Devices in COPD (clinicaltrials.gov) - Feb 14, 2022
P4, N=24, Completed, Sponsor: University Hospital, Bordeaux
Trial completion date: Aug 2021 --> Jun 2022 | Trial primary completion date: Aug 2021 --> Dec 2021 Not yet recruiting --> Completed
- || Blenrep (belantamab mafodotin-blmf) / GSK
Phase classification, Trial completion date, Trial primary completion date, Combination therapy: DREAMM-6: To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (clinicaltrials.gov) - Feb 14, 2022
P2, N=152, Recruiting, Sponsor: GlaxoSmithKline
Not yet recruiting --> Completed Phase classification: P1/2 --> P2 | Trial completion date: Aug 2022 --> Aug 2023 | Trial primary completion date: Apr 2022 --> Feb 2023
- ||| Decadron (dexamethasone) / Merck (MSD)
It is endemic in the SE too,we implemented screening all pre OHT R at my previous institution. We treated all + ab prior to OHT. Of note, ab + even after treatment, also never seen hyper infection w steroids personally, in c19 I'm assuming you're talking of short course decadron. (Twitter) - Feb 14, 2022
- | Trial completion: Effectiveness of Premedication on the Success Rate of Inferior Alveolar Nerve Block (clinicaltrials.gov) - Feb 14, 2022
P=N/A, N=250, Completed, Sponsor: Alfarabi Colleges
Phase classification: P1/2 --> P2 | Trial completion date: Aug 2022 --> Aug 2023 | Trial primary completion date: Apr 2022 --> Feb 2023 Recruiting --> Completed
- || budesonide / Generic mfg.
Crap in crap out 1600 ug budesonide in Principle has appreciable systemic glucocorticoid activity so that it’s impossible invoke any local effect especially as alveolar deposition is low . (Twitter) - Feb 13, 2022
- | latanoprost / Generic mfg., dexamethasone injection / Generic mfg.
Journal: Stanniocalcin-1 Reduced Intraocular Pressure in Two Models of Ocular Hypertension. (Pubmed Central) - Feb 12, 2022
In DBA/2J mice, STC-1 lowered IOP by 37% (P < .001). Together, these data show that STC-1 reduced IOP in two models of ocular hypertension with different mechanisms of outflow obstruction.